Cogent Biosciences, Inc.

NASDAQ:COGT

Biotechnology

Healthcare
$27.81 +2.60%

+$0.88 today

Market cap
$4.84B
Beta
0.35
P/E (TTM)
-6.6
EPS (TTM)
-$5.26
52W Low $6.92High $43.73

Volume 2.71M

Average 2.15M

COGT Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Cogent Biosciences, Inc.NASDAQ: COGT

Operating Margin · Q2 FY2026 · quarter ended Jun 2026

Operating margin not reported for Q2 FY2026

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
—— QoQ
Last fiscal yearDec 2025
—— YoY
LTMJun 2026
—— YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Operating Margin history

Percent of revenue · from the income statement

No Operating Margin data reported for this period type.

Operating Margin vs competitors

How COGT compares with its peers on the latest reported figures

COGT Competitors Peer median
Operating Margin for COGT and competitors
Company Period LTM level YoY 3-year change
NRIXNurix Therapeutics, Inc.LTM Aug 202641.3% +360.6 pp+135.8 pp
INCYIncyte CorporationLTM Jun 202631.6% +10.4 pp+8.7 pp
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-81.4% +5066.4 pp+49.9 pp
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026-102.9% +683.7 pp—
TNGXTango Therapeutics, Inc.FY2025-178.4% +167.7 pp+268.4 pp
RCUSArcus Biosciences, Inc.LTM Jun 2026-415.4% -286.4 pp+93.7 pp
KURAKura Oncology, Inc.LTM Mar 2026-443.5% -144.3 pp—
MAZEMaze Therapeutics, Inc.LTM Mar 2026-670.3% -700.2 pp—
COGTCogent Biosciences, Inc.FY2025— ——
AVBPArriVent BioPharma, Inc. Common StockFY2025— ——
Peer median (excluding COGT) -140.7%+89.0 pp+93.7 pp

Competitors are the stored peer set for COGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00004.62M
Gross Profit0000(4.62M)
Gross Margin—————
Research & Development55.91M121.63M173.76M232.66M269.78M
Selling, General & Admin19.64M26.21M34.38M43.28M63.58M
Operating Expenses75.55M147.84M208.13M275.94M328.74M
Depreciation & Amortization147K5.88M3.59M4.35M4.58M
EBITDA(72.13M)(130.37M)(188.82M)(251.51M)(321.29M)
EBITDA Margin—————
Operating Income(75.55M)(147.84M)(208.13M)(275.94M)(333.36M)
Operating Margin—————
Interest Income467K3.99M13.08M18.09M14.69M
Interest Expense03.99M003.06M
Other Income / Expenses3.28M7.6M15.72M20.08M4.43M
Income Before Tax(72.27M)(140.24M)(192.41M)(255.86M)(328.94M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(72.27M)(140.24M)(192.41M)(255.86M)(328.94M)
Net Margin—————
EPS (Basic)(1.85)(2.26)(2.42)(2.32)(2.04)
EPS (Diluted)(1.85)(2.26)(2.42)(2.32)(2.04)
Weighted Avg Shares38.73M58.74M79.66M110.46M160.98M
Weighted Avg Shares (Diluted)38.73M58.74M79.66M110.46M160.98M

Cogent Biosciences, Inc.

NASDAQ:COGT

Intrinsic Alpha fair value

Locked

Current Price

$27.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.